ZYNE
Income statement / Annual
Last year (2022), Zynerba Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Zynerba Pharmaceuticals, Inc.'s net income was -$34.82 M.
See Zynerba Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$86,000.00
|
$7,250.00
|
$7,250.00
|
$278,900.00
|
$810,012.00
|
$943,904.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$86,000.00 |
$7,250.00 |
$7,250.00 |
$278,900.00 |
$810,012.00 |
$943,904.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$21.10 M
|
$21.42 M
|
$35.65 M
|
$20.38 M
|
$27.25 M
|
$22.81 M
|
$16.78 M
|
$7.45 M
|
$2.40 M
|
$1.13 M
|
| General & Administrative
Expenses |
$14.15 M
|
$15.35 M
|
$16.41 M
|
$13.94 M
|
$13.24 M
|
$10.02 M
|
$6.43 M
|
$5.36 M
|
$4.08 M
|
$444,302.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$14.15 M
|
$15.35 M
|
$16.41 M
|
$13.94 M
|
$13.24 M
|
$10.02 M
|
$6.43 M
|
$5.36 M
|
$4.08 M
|
$444,302.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$35.25 M |
$36.77 M |
$52.06 M |
$34.32 M |
$40.48 M |
$32.82 M |
$23.21 M |
$12.81 M |
$6.48 M |
$1.58 M |
| Cost And Expenses |
$35.25 M |
$36.77 M |
$52.06 M |
$34.32 M |
$40.48 M |
$32.82 M |
$23.21 M |
$12.81 M |
$6.48 M |
$1.58 M |
| Interest Income |
$846,860.00 |
$21,047.00 |
$243,992.00 |
$1.52 M |
$961,323.00 |
$519,554.00 |
$80,222.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
-$215,734.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$631,126.00
|
$559,681.00
|
-$481,719.00
|
$145,911.00
|
$99,572.00
|
$94,211.00
|
$75,301.00
|
$26,027.00
|
$27,063.00
|
$49,392.00
|
| EBITDA |
-$34.62 M
|
-$36.21 M
|
-$52.06 M
|
-$34.17 M
|
-$40.40 M
|
-$32.82 M
|
-$23.21 M
|
-$12.51 M
|
-$5.64 M
|
-$585,047.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
-464.22 |
-4567.47 |
-3161.24 |
-44.84 |
-6.96 |
-0.62 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
-469.74
|
-4527.31
|
-3201.05
|
-44.93
|
-7
|
-0.67
|
| Total Other
Income/Expenses Net |
$215,734.00
|
-$538,634.00
|
$725,711.00
|
$1.38 M
|
$486,655.00
|
$810,705.00
|
-$208,422.00
|
$7,352.00
|
-$1,844.00
|
-$2,351.00
|
| Income Before Tax |
-$35.04 M |
-$37.31 M |
-$51.34 M |
-$32.94 M |
-$39.91 M |
-$32.01 M |
-$23.42 M |
-$12.52 M |
-$5.67 M |
-$636,790.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
-464.08
|
-4415.49
|
-3229.8
|
-44.9
|
-7
|
-0.67
|
| Income Tax Expense |
-$215,734.00 |
$291,494.00 |
-$932,746.00 |
-$1.51 M |
$486,655.00 |
-$27,543.00 |
-$27,543.00 |
$27,543.00 |
$0.00 |
$0.00 |
| Net Income |
-$34.82 M |
-$37.60 M |
-$50.40 M |
-$31.43 M |
-$39.91 M |
-$32.01 M |
-$23.39 M |
-$12.55 M |
-$5.67 M |
-$636,790.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
-464.08 |
-4415.49 |
-3226 |
-45 |
-7 |
-0.67 |
| EPS |
-0.82 |
-0.96 |
-1.87 |
-1.43 |
-2.61 |
-2.48 |
-2.58 |
-2.82 |
-0.99 |
-0.11 |
| EPS Diluted |
-0.82 |
-0.96 |
-1.87 |
-1.43 |
-2.61 |
-2.48 |
-2.58 |
-2.82 |
-0.99 |
-0.11 |
| Weighted Average Shares
Out |
$42.66 M
|
$39.26 M
|
$27.02 M
|
$22.00 M
|
$15.31 M
|
$12.91 M
|
$9.07 M
|
$4.46 M
|
$5.73 M
|
$5.73 M
|
| Weighted Average Shares
Out Diluted |
$42.66 M
|
$39.26 M
|
$27.02 M
|
$22.00 M
|
$15.31 M
|
$12.91 M
|
$9.07 M
|
$4.46 M
|
$5.73 M
|
$5.73 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
